Granules India approves internal restructuring of US subsidiaries

Granules India (BSE: GRANULES) announced on March 25, 2025, that its Board of Directors approved an internal restructuring plan for its wholly-owned subsidiaries in the United States. The plan aims to simplify the organization structure, consolidate business operations, and reduce the number of legal entities. As part of the restructuring, Granules USA, Inc. (GUSA) will transfer its business and assets to Granules Pharmaceutical, Inc. (GPI). The company expects that the plan will create a unified holding structure, improve market focus, and lead to simplification of legal, tax, and operational aspects. The company clarifies that the restructuring will be accounted for as a common control transaction at carrying values and will not change the ultimate ownership or nature of the business in the US. The restructuring is effective as of March 25, 2025.